Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03436563 · ClinicalTrials.gov registry record · Phase 1
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03436563: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03436563 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03436563, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase Ib/II trial studies how well anti-PD-L1/TGFbetaRII fusion protein M7824 (M7824) works in treating patients with colorectal cancer (or with other solid tumors with microsatellite instability) that has spread to other places in the body or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as M7824, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Interventions
- BIOLOGICAL Anti-PD-L1/TGFbetaRII Fusion Protein M7824
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-03-07 |
| Est. Completion | 2023-08-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03436563
The ClinicalTrials.gov registry entry for NCT03436563 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anti-PD-L1/TGFbetaRII Fusion Protein M7824 is the first listed.
NCT03436563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03436563 about?
NCT03436563 is a clinical study titled "M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability". This phase Ib/II trial studies how well anti-PD-L1/TGFbetaRII fusion protein M7824 (M7824) works in treating patients with colorectal cancer (or with other solid tumors with microsatellite instability) that has spread to other places in the body or cannot be removed by surgery. Immunotherapy with mo...
What is the current status of trial NCT03436563?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2018-03-07. Estimated completion is 2023-08-08.
What interventions are being tested in trial NCT03436563?
The interventions under investigation include: Anti-PD-L1/TGFbetaRII Fusion Protein M7824 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03436563?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.